SOUVIE BIODELIVERY LLC

Biotech · Private

Engineered exosome-based delivery platform carrying anti-TLR7 antibodies to target endosomal inflammation in autoimmune diseases

Grants
$225K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Novel drug delivery system using engineered exosomes$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2998End2End Genomics LLC——
2999Tolerance Bio Inc.—$15M
3000IMMUNOBLUE, LLC——
3001SOUVIE BIODELIVERY LLC——
3002Riboscience LLC——
3003AAIIT LLC——
3004Structure Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • Compositions And Methods For Treating Toll-like Receptor-driven Inflammatory Diseasesapplication
  • Compositions And Methods For Treating Toll-like Receptor-driven Inflammatory Diseasesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.